Impact of platelet glycoprotein IIb/IIIa inhibition on the Paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (A TAXUS IV substudy)

American Journal of Cardiology

Volumn 96, Issue 4, 2005, Pages 500-505

  Teirstein, Paul S ^a   Kao, John ^a   Watkins, Matthew ^b   Tannenbaum, Mark A ^c   Laufer, Nathan ^d   Chang, Michael ^e   Mehran, Roxana ^h   Dangas, George ^h   Russell, Mary E ^f   Ellis, Stephen G ^g   Stone, Gregg W ^h  

^a SCRIPPS CLINIC   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

^c Mercy Hospital Medical Center   (United States)

^d BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^e Mercy General Hospital   (United States)

^f BOSTON SCIENTIFIC CORPORATION   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CREATINE KINASE; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TREATMENT OUTCOME; TYROSINE;

EID: 23744488959     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.04.009     Document Type: Article

References (20)

1. M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. O'Shaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg TAXUS-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
4. P.W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne The Benestent Study Group A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 331 1994 489 495
5. A. Kastrati, A. Schömig, J. Dirschinger, J. Mehilli, F. Dotzer, N. von Welser, F.J. Neumann A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease intracoronary stenting or angioplasty for restenosis in small arteries Circulation 102 2000 2593 2598
6. S.C. Smith Jr, J.T. Dove, A.K. Jacobs, J.W. Kennedy, D. Kereiakes, M.J. Kern, R.E. Kuntz, J.J. Popma, H.V. Schaff, D.O. Williams ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions Circulation 103 2001 3019 3041
7. The EPIC Investigators Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty evaluation of 7e3 for the prevention of ischemic complications N Engl J Med 330 1994 956 961
8. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade N Engl J Med 336 1997 1689 1696
9. The IMPACT-II Investigators Randomized, placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II Lancet 349 1997 1422 1428
10. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
11. The EPISTENT Investigators Randomized placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade Lancet 352 1998 87 92
12. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomized, placebo-controlled trial Lancet 356 2000 2037 2044
13. E. Karvouni, D.G. Katritsis, J.P. Ioannidis Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions J Am Coll Cardiol 41 2003 26 32
14. K.M. Anderson, R.M. Califf, G.W. Stone, F.J. Neumann, G. Montalescot, D.P. Miller, J.J. Ferguson, J.T. Willerson, H.F. Weisman, E.J. Topol Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J Am Coll Cardiol 37 2001 2059 2065
15. A.W. Bonz, B. Lengenfelder, J. Strotmann, S. Held, O. Turschner, K. Harre, C. Wacker, C. Waller, N. Kochsiek, M. Meesmann Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) J Am Coll Cardiol 40 2002 662 668
16. J.F. Saucedo, R. Mehran, G. Dangas, M.K. Hong, A. Lansky, K.M. Kent, L.F. Satler, A.D. Pichard, G.W. Stone, M.B. Leon Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting J Am Coll Cardiol 35 2000 1134 1141
17. A.E. Abdelmeguid, E.J. Topol, P.L. Whitlow, S.K. Sapp, S.G. Ellis Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions Circulation 94 1996 1528 1536
18. S.G. Ellis, D. Chew, A. Chan, P.L. Whitlow, J.P. Schneider, E.J. Topol Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy Circulation 106 2002 1205 1210
19. A.J. Lansky, R.A. Costa, G.S. Mintz, Y. Tsuchiya, M. Midei, D.A. Cox, C. O'Shaughnessy, R.A. Applegate, L.A. Cannon, M. Mooney DELIVER Clinical Trial Investigators Non-polymer-based paclitaxel coated coronary stents for the treatment of patients with de novo coronary lesions - angiographic follow-up of the DELIVER clinical trial Circulation 109 2004 1948 1954
20. I. Iakovou, G.S. Mintz, G. Dangas, A. Abizaid, R. Mehran, Y. Kobayashi, A.J. Lansky, E.D. Aymong, E. Nikolsky, G.W. Stone Increased CK-MB release is a "trade-off" for optimal stent implantation an intravascular ultrasound study J Am Coll Cardiol 42 2003 1900 1905